Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty.
Fareed
J
J
Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153.
Walenga
J M
JM
Leya
F
F
Bacher
P
P
Hoppensteadt
D
D
Messmore
H
H
Pifarre
R
R
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006493:Heparin / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D006493:Heparin